These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35710397)

  • 1. KAZN as a diagnostic marker in ovarian cancer: a comprehensive analysis based on microarray, mRNA-sequencing, and methylation data.
    Zhu S; Bao H; Zhang MC; Liu H; Wang Y; Lin C; Zhao X; Liu SL
    BMC Cancer; 2022 Jun; 22(1):662. PubMed ID: 35710397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer.
    Singh A; Gupta S; Badarukhiya JA; Sachan M
    Int J Cancer; 2020 Sep; 147(6):1740-1752. PubMed ID: 32191343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relationships between decreased LAMC3 and poor prognosis in ovarian cancer].
    Lei SM; Liu X; Xia LP; Ke Y; Wei LW; Li L; Yin FJ
    Zhonghua Fu Chan Ke Za Zhi; 2021 Jul; 56(7):489-497. PubMed ID: 34304441
    [No Abstract]   [Full Text] [Related]  

  • 4. Plasma cfDNA methylation markers for the detection and prognosis of ovarian cancer.
    Liang L; Zhang Y; Li C; Liao Y; Wang G; Xu J; Li Y; Yuan G; Sun Y; Zhang R; Li X; Nian W; Zhao J; Zhang Y; Zhu X; Wen X; Cai S; Li N; Wu L
    EBioMedicine; 2022 Sep; 83():104222. PubMed ID: 35973389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers.
    Huang RL; Gu F; Kirma NB; Ruan J; Chen CL; Wang HC; Liao YP; Chang CC; Yu MH; Pilrose JM; Thompson IM; Huang HC; Huang TH; Lai HC; Nephew KP
    Epigenetics; 2013 Jun; 8(6):624-34. PubMed ID: 23774800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility.
    Marinelli LM; Kisiel JB; Slettedahl SW; Mahoney DW; Lemens MA; Shridhar V; Taylor WR; Staub JK; Cao X; Foote PH; Burger KN; Berger CK; O'Connell MC; Doering KA; Giakoumopoulos M; Berg H; Volkmann C; Solsrud A; Allawi HT; Kaiser M; Vaccaro AM; Albright Crawford C; Moehlenkamp C; Shea G; Deist MS; Schoolmeester JK; Kerr SE; Sherman ME; Bakkum-Gamez JN
    Gynecol Oncol; 2022 Jun; 165(3):568-576. PubMed ID: 35370009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer.
    Dong C; Yin F; Zhu D; Cai X; Chen C; Liu X
    J Cell Biochem; 2020 Nov; 121(11):4470-4483. PubMed ID: 32030795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer.
    Jiao J; Jiang L; Luo Y
    Recent Pat Anticancer Drug Discov; 2021; 16(3):407-416. PubMed ID: 34137363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
    Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
    Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis.
    Kalachand RD; Stordal B; Madden S; Chandler B; Cunningham J; Goode EL; Ruscito I; Braicu EI; Sehouli J; Ignatov A; Yu H; Katsaros D; Mills GB; Lu KH; Carey MS; Timms KM; Kupryjanczyk J; Rzepecka IK; Podgorska A; McAlpine JN; Swisher EM; Bernards SS; O'Riain C; O'Toole S; O'Leary JJ; Bowtell DD; Thomas DM; Prieske K; Joosse SA; Woelber L; Chaudhry P; Häfner N; Runnebaum IB; Hennessy BT
    J Natl Cancer Inst; 2020 Dec; 112(12):1190-1203. PubMed ID: 32413141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased Expression of
    Zou R; Xu H; Li F; Wang S; Zhu L
    DNA Cell Biol; 2021 Jan; 40(1):36-60. PubMed ID: 33180631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic profiling and mRNA expression reveal candidate genes as biomarkers for colorectal cancer.
    Zhang H; Dong S; Feng J
    J Cell Biochem; 2019 Jun; 120(6):10767-10776. PubMed ID: 30672027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of Epithelial Splicing Regulatory Protein 1 in Metastatic Lesions of Serous Ovarian Carcinoma Correlates with Poor Patient Prognosis.
    Lu X; Li R; Wang X; Guo Q; Wang L; Zhou X
    Cancer Biother Radiopharm; 2022 Nov; 37(9):850-861. PubMed ID: 34495766
    [No Abstract]   [Full Text] [Related]  

  • 14. Comprehensive DNA methylation profiling by MeDIP-NGS identifies potential genes and pathways for epithelial ovarian cancer.
    Gautam P; Gupta S; Sachan M
    J Ovarian Res; 2024 Apr; 17(1):83. PubMed ID: 38627856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer.
    Häfner N; Steinbach D; Jansen L; Diebolder H; Dürst M; Runnebaum IB
    Int J Cancer; 2016 Jan; 138(1):217-28. PubMed ID: 26175272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Analysis of the Expression and Prognosis for Laminin Genes in Ovarian Cancer.
    Diao B; Yang P
    Pathol Oncol Res; 2021; 27():1609855. PubMed ID: 34512203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor 2 mRNA-binding protein 2 is a therapeutic target in ovarian cancer.
    Yuan J; Li X; Wang F; Liu H; Guan W; Xu G
    Exp Biol Med (Maywood); 2023 Dec; 248(23):2198-2209. PubMed ID: 38084732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer.
    Wu Y; Zhang X; Lin L; Ma XP; Ma YC; Liu PS
    Asian Pac J Cancer Prev; 2014; 15(3):1171-6. PubMed ID: 24606436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant Hypomethylation of Solute Carrier Family 6 Member 12 Promoter Induces Metastasis of Ovarian Cancer.
    Sung HY; Yang SD; Park AK; Ju W; Ahn JH
    Yonsei Med J; 2017 Jan; 58(1):27-34. PubMed ID: 27873492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
    Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
    Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.